José Raimundo Araujo de Azevedo

Quick facts

Phase 2 pipeline

• Escherichia coli ESBL · Infectious Disease
  This appears to be a therapeutic intervention targeting extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli infections.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• José Raimundo Araujo de Azevedo portfolio CI brief
• José Raimundo Araujo de Azevedo pipeline updates RSS